MX2023009538A - Ligandos de cxcr4 para uso diagnostico y terapeutico, y precursores de los mismos. - Google Patents
Ligandos de cxcr4 para uso diagnostico y terapeutico, y precursores de los mismos.Info
- Publication number
- MX2023009538A MX2023009538A MX2023009538A MX2023009538A MX2023009538A MX 2023009538 A MX2023009538 A MX 2023009538A MX 2023009538 A MX2023009538 A MX 2023009538A MX 2023009538 A MX2023009538 A MX 2023009538A MX 2023009538 A MX2023009538 A MX 2023009538A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- sub
- cxcr4 receptor
- cxcr4
- diagnostic
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000002243 precursor Substances 0.000 title 1
- 108010061299 CXCR4 Receptors Proteins 0.000 abstract 4
- 102000012000 CXCR4 Receptors Human genes 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 239000013256 coordination polymer Substances 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención proporciona un compuesto de ligando del receptor CXCR4 de fórmula (I) o una sal del mismo: (ver Fórmula) (I) en donde: a es 0 o 1; b es 0 o 1; c es 0 o 1, y d es 0 o 1, con la condición de que al menos uno de c y d sea 1; e es un número entero de 1 a 4; RCP es un motivo de unión que permite que el compuesto se una al receptor CXCR4; RL1 es H o alquilo; RL2 es alquilo sustituido, cuyo alquilo sustituido está sustituido con al menos un grupo seleccionado de -NH2 y -NH-C(=X)-NH2 seleccionándose X de NH y O; RL3 es -CH2-NH2 o -CH2-(1H-imidazol-4-il); RL4 es -NH2; X1 es un grupo de acoplamiento; RS es un grupo espaciador divalente; y RA es un grupo funcional que comprende una fracción con utilidad diagnóstica o terapéutica. Los compuestos de la invención son adecuados para su uso en el tratamiento, prevención y/o diagnóstico de una enfermedad o trastorno que puede tratarse o prevenirse mediante el bloqueo del receptor CXCR4, o que está asociado con una expresión aumentada o anómala del receptor CXCR4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21157225.0A EP4043041A1 (en) | 2021-02-15 | 2021-02-15 | Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof |
| PCT/EP2022/053528 WO2022171869A1 (en) | 2021-02-15 | 2022-02-14 | Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009538A true MX2023009538A (es) | 2023-08-25 |
Family
ID=74625931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009538A MX2023009538A (es) | 2021-02-15 | 2022-02-14 | Ligandos de cxcr4 para uso diagnostico y terapeutico, y precursores de los mismos. |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP4043041A1 (es) |
| JP (1) | JP2024506700A (es) |
| CN (1) | CN117042812A (es) |
| AU (1) | AU2022219294A1 (es) |
| CA (1) | CA3204021A1 (es) |
| CO (1) | CO2023010579A2 (es) |
| MX (1) | MX2023009538A (es) |
| WO (1) | WO2022171869A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202207372D0 (en) * | 2022-05-19 | 2022-07-06 | Blue Earth Diagnostics Ltd | Synthesis of fluorosilyl compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2426139B1 (en) | 2002-08-27 | 2014-10-01 | Biokine Therapeutics Ltd. | CXCR4 antagonist and use thereof |
| CA2643744A1 (en) | 2006-02-27 | 2007-08-30 | Technische Universitaet Muenchen | Cancer imaging and treatment |
| WO2008075370A2 (en) | 2006-12-21 | 2008-06-26 | Biokine Therapeutics Ltd. | T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy |
| CL2008001467A1 (es) | 2007-05-30 | 2008-12-05 | Lilly Co Eli | Peptidos cilindricos antagonistas de cxcr4 ciclado por lactamas: composicion farmaceutica que los comprenden; y su uso para tratar artitis reumatica, fibrosis pulmonar, infeccion por vih o cancer. |
| GB0716897D0 (en) | 2007-08-30 | 2007-10-10 | Univ Muenchen Tech | Cancer imaging and treatment |
| EP2380596A1 (en) | 2010-04-20 | 2011-10-26 | Technische Universität München | Cyclopentapeptide derivatives and uses thereof |
| WO2012118124A1 (ja) | 2011-03-01 | 2012-09-07 | 国立大学法人京都大学 | 新規ケモカイン受容体拮抗剤 |
| CN102626522B (zh) * | 2012-04-12 | 2014-09-10 | 韩彦江 | 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物 |
| WO2015185162A1 (en) | 2014-06-06 | 2015-12-10 | Technische Universität München | Modified cyclopentapeptides and uses thereof |
| US11639373B2 (en) | 2018-09-12 | 2023-05-02 | Technische Universität München | Therapeutic and diagnostic agents for cancer |
-
2021
- 2021-02-15 EP EP21157225.0A patent/EP4043041A1/en not_active Withdrawn
-
2022
- 2022-02-14 CA CA3204021A patent/CA3204021A1/en active Pending
- 2022-02-14 MX MX2023009538A patent/MX2023009538A/es unknown
- 2022-02-14 JP JP2023549039A patent/JP2024506700A/ja active Pending
- 2022-02-14 EP EP22709980.1A patent/EP4291252A1/en active Pending
- 2022-02-14 WO PCT/EP2022/053528 patent/WO2022171869A1/en active Application Filing
- 2022-02-14 AU AU2022219294A patent/AU2022219294A1/en active Pending
- 2022-02-14 CN CN202280015035.5A patent/CN117042812A/zh active Pending
-
2023
- 2023-08-14 CO CONC2023/0010579A patent/CO2023010579A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024506700A (ja) | 2024-02-14 |
| EP4043041A1 (en) | 2022-08-17 |
| WO2022171869A1 (en) | 2022-08-18 |
| EP4291252A1 (en) | 2023-12-20 |
| AU2022219294A1 (en) | 2023-07-06 |
| CA3204021A1 (en) | 2022-08-18 |
| CN117042812A (zh) | 2023-11-10 |
| CO2023010579A2 (es) | 2023-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2495044C2 (ru) | Ингибиторы активности протеинтирозинкиназы | |
| RU2324684C2 (ru) | Пиримидиновые производные | |
| RU2014153920A (ru) | Дигидронафтиридины и родственные соединения, подходящие в качестве ингибиторов киназ для лечения пролиферативных заболеваний | |
| RU2010126056A (ru) | Органические соединения | |
| KR20180021117A (ko) | 아르기나제 활성 억제를 위한 조성물 및 방법 | |
| MX2023009538A (es) | Ligandos de cxcr4 para uso diagnostico y terapeutico, y precursores de los mismos. | |
| JP2010530881A5 (es) | ||
| RU2010107284A (ru) | Производные нафтиридина в качестве модуляторов калиевых каналов | |
| MX2009013581A (es) | Derivados de 4-(n-azacicloalquil)anilidas como moduladores del canal de potasio. | |
| US4277466A (en) | Complexes of DNA and esters derived from daunorubicine, their preparation and use | |
| AU2014297144B2 (en) | Novel biphenyl derivative and method for preparing same | |
| SK18332002A3 (sk) | Farmaceutický prostriedok obsahujúci farmaceuticky prijateľný nosič alebo masťový základ a ako aktívnu prísadu derivát akryloyldistamycínu a inhibítor topoizomerázy I a II | |
| TWI284643B (en) | Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione | |
| KR100869037B1 (ko) | 치환된 아크릴로일 디스타마이신 유도체 및 알킬화제를 포함하는 항종양 조성물 | |
| EP1868599B1 (en) | Antitumor combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors | |
| AU2001281867A1 (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents | |
| DE69735383T2 (de) | Methode zur Inhibierung von HEREGULIN und seines Rezeptors sowie Verwendung zur Inhibierung von Krebszellen | |
| CHEN et al. | Central nervous action of hydantoins, oxazolidinediones and thiazolidones | |
| CA2472008C (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors | |
| US20120295871A1 (en) | Heparin-based compositions and methods for the inhibition of metastasis | |
| WO1998021956A9 (en) | Heregulin antagonists and methods for their use | |
| RU2190399C2 (ru) | Средство для лечения и предотвращения кахексии | |
| RU2024104810A (ru) | 6-аминопиразолопиримидиновые соединения их применение в медицине | |
| JP2022511746A (ja) | 高リスクの、および非常に高リスクのｍｄｓのための併用療法 | |
| JP5148941B2 (ja) | スルフォスチン、及びスルフォスチン関連化合物を有効成分とした抗腫瘍剤 |